Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US02043Q1076
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BFGNJ5
ALNY
Alnylam Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Alnylam Pharmaceuticals Inc
ISIN
US02043Q1076
TICKER
ALNY
MIC
XNAS
REUTERS
ALNY.OQ
BLOOMBERG
ALNY US
Mo., 05.05.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the C...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 01.05.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. “2025 is off to a remarkable start, having ended the first quarter with U.S. regulatory approval of AMVUTTRA for ATTR-CM. This im...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 28.04.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hered...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 17.04.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 01.04.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Sa., 29.03.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. Data we...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 28.03.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 20.03.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloid...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 11.03.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnyla...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 05.03.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company’s Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnyl...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 25.02.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent bloc...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 13.02.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights. “2024 was another year of impressive execution for Alnylam, generating product revenues of over $1.6 billion,...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
So., 12.01.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GAAP operating income profitability, and pipeline goals gui...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 06.01.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 27.11.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 25.11.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyop...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
So., 17.11.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 04.11.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at the Terranea Resort in Ranchos Palos Verdes, CA Jefferies London Healthcare...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 31.10.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. “Alnylam continued to deliver robust results commercially and clinically in the third quarter. We achieved 34% year-over-year...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 30.10.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA) Scientific Sessions 2024, November 16–18, 2024. Data presentations for the Company’s flagship T...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 17.10.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2024 on Thursday, October 31, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2024 results as...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 16.10.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is th...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
So., 29.09.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Sess...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 26.09.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, October 9, 2024 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the ev...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 30.08.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the Eur...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 28.08.2024       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 9:30 am ET in Boston Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday,...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 24.06.2024       Alnylam Pharmaceuticals
US02043Q1076

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US02043Q1076 SIND AB 13:40 CET WIEDER IN DEN HANDEL AUFGENOMMEN. ALL STRUCTURED PRODUCTS WITH UNDERLYING US02043Q1076 ARE RESUMED TRADING FROM ONWARDS 13:40 CET....
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 24.06.2024       Alnylam Pharmaceuticals
US02043Q1076

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US02043Q1076 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES. ALL STRUCTURED PRODUCTS WITH UNDERLYING US02043Q1076 ARE SUSPENDED UNTIL FURTHER NOTICE....
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 24.06.2024       Alnylam Pharmaceuticals
US02043Q1076

Instrument ID [6797] (DUL - US02043Q1076) suspended...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 05.03.2024       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - March 5, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Alnylam...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 26.02.2024       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - February 26, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aln...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 30.11.2023       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - November 30, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aln...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 17.11.2023       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - November 17, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aln...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 09.11.2023       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - November 9, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Alny...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 01.11.2023       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - November 1, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Alny...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 23.10.2023       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - October 23, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Alny...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
So., 15.10.2023       Alnylam Pharmaceuticals
US02043Q1076

New York, New York--(Newsfile Corp. - October 15, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Alny...
Zur Nachricht
Alnylam Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink